WASHINGTON, DC — The Biosimilars Council applauds the unanimous Senate passage of the Affordable Prescriptions for Patients Act led by Senator Cornyn (R-TX) and Senator Blumenthal (D-CT). The bill is aimed at reforming patent abuse in the pharmaceutical industry.“The Biosimilars Council and AAM applauds unanimous Senate passage of the Cornyn-Blumenthal legislation,” said Craig Burton, executive director of the biosimilars council. “Patent thickets are used by brand pharmaceutical companies to maintain high prices and deny patients access to lower-cost medicines. This legislation is a great step in curbing these abuses and will help increase competition and access for biosimilars. We encourage the House to take up this legislation and for Congress to continue working to help lower costs for patients.”
Biosimilars Council applauds patent abuse act
The Biosimilars Council applauds the unanimous Senate passage of the Affordable Prescriptions for Patients Act led by Senator Cornyn (R-TX) and Senator Blumenthal (D-CT). The bill is aimed at reforming patent abuse in the pharmaceutical industry.
Latest
NACDS submits comments to FDA on expanding access to nonprescription drugs
Comments emphasize the importance of coordinated policy and operational alignment to support affordable and seamless patient access.
Rula teams with ice cream brand Van Leeuwen to launch "Therapy in a Pint"
In honor of Mental Health Awareness Month, the collaboration builds on the joy of ice cream by encouraging deeper self-care through 'Therapy in a Pint.'
Aetna Better Health of Missouri collaborates with local organizations to address food insecurity
The funding will expand access to nutritious foods, strengthen farm sustainability and enhance safety and wellness supports, such as a women’s shelter and diaper bank.
New launch from TheraTears targets dry, screen-fatigued eyes
The innovative solutions are designed to support everyday eye comfort with gentle cleansing and dry eye relief for consumers experiencing screen-related eye fatigue.